Blue Blooded
Most people rejected his message
Skjei signing long-term at 6.6% very similar to Orlov, Theodore. I think those are good comparables for Skjei and probably why he got what was given to him.
Skjei: 3 RFA, 3 UFA
Orlov: 2 RFA, 4 UFA
Theodore: 5 RFA, 2 UFA
Hanifin: 4 RFA, 2 UFA
Gostisbehere: 5 RFA, 1 UFA
It's difficult to find exact comparisons due to age difference and RFA/UFA splits but I think 5.25m AAV is good value for a player like Brady Skjei. The Rangers took a risk. The alternative would be a 3.5m AAV for 2 more seasons, and then giving him a 7m AAV in 2020 long-term with only 1 RFA year to buy out, a higher salary cap etc. Now we have Skjei for 5.25m until 2024.
No way Skjei was ever going to get $7M in 2020, that's preposterous. His 39 point season was an anomaly (as I briefly explained in the earlier post), he's never shown that kind of offensive upside before or after that season.
Skjei was excellent in 2017-18 but even if he kept up that level of play (which he is extremely far off so far this season) throughout his bridge deal he'd be looking at an $5.5-$5.7M AAV on his next deal at the very most. Especially considering he still got PP time in 2017-18 and he isn't going to get more than a handful of PP minutes in 2018-19 nor in 2019-20 because he just isn't a good PP player.
If he continues his 2018-19 level of play in 2019-20 we would probably have been able to extend Skjei below a $4M AAV come 2020.